{"filing":{"accession_number":"0001493152-26-038663","cik":"0001595353","ticker":"GLMD","company_name":"Galmed Pharmaceuticals Ltd.","form":"6-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595353/000149315226038663/form6-k.htm"},"events":[{"id":28173,"run_id":25756,"accession_number":"0001493152-26-038663","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces pre-clinical research results showing that Aramchol (Galmed's SCD1 inhibitor) demonstrates a 3–4-fold increase in cell death when combined with enzalutamide in prostate cancer models. The disclosure is a material operational/strategic milestone for a clinical-stage biopharmaceutical company: it presents novel scientific data supporting a potential combination therapy strategy, identifies a large market opportunity (Xtandi's ~$6–8 billion annual sales), and indicates the company plans to initiate partnership discussions based on a recently submitted patent application. While not a discrete M\u0026A transaction or earnings release, this represents a material advancement in the company's oncology pipeline and commercial strategy.","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-08-17","form":"6-K","submitted_at":null,"items":[{"id":30014,"accession_number":"0001493152-26-038663","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces pre-clinical research results showing that Aramchol (Galmed's SCD1 inhibitor) demonstrates a 3–4-fold increase in cell death when combined with enzalutamide in prostate cancer models. The disclosure is a material operational/strategic milestone for a clinical-stage biopharmaceutical company: it presents novel scientific data supporting a potential combination therapy strategy, identifies a large market opportunity (Xtandi's ~$6–8 billion annual sales), and indicates the company plans to initiate partnership discussions based on a recently submitted patent application. While not a discrete M\u0026A transaction or earnings release, this represents a material advancement in the company's oncology pipeline and commercial strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T13:21:43.107541+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30014,"accession_number":"0001493152-26-038663","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces pre-clinical research results showing that Aramchol (Galmed's SCD1 inhibitor) demonstrates a 3–4-fold increase in cell death when combined with enzalutamide in prostate cancer models. The disclosure is a material operational/strategic milestone for a clinical-stage biopharmaceutical company: it presents novel scientific data supporting a potential combination therapy strategy, identifies a large market opportunity (Xtandi's ~$6–8 billion annual sales), and indicates the company plans to initiate partnership discussions based on a recently submitted patent application. While not a discrete M\u0026A transaction or earnings release, this represents a material advancement in the company's oncology pipeline and commercial strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T13:21:43.107541+00:00","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-08-17"}]}